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Background: Sulfotransferase 1A1 (SULT1A1) gene expression is tissue specific, with little to no expression in normal
breast epithelia. Expression in breast tumors has been documented, but the transcriptional regulation of SULT1A1 in
human breast tissue is poorly understood. We identified Nuclear Factor I (NFI) as a transcription factor family
involved in the regulation of SULT1A1 expression.
Methods: Transcription Factor Activation Profiling Plate Array assay was used to identify the possible transcription
factors that regulate the gene expression of SULT1A1in normal breast MCF-10A cells and breast cancer ZR-75-1 cells.
Expression levels of NFI-C and SULT1A1 were determined by real-time RT-PCR using total RNA isolated from 84
human liver samples. Expression levels of SULT1A1, NFI-A, NFI-B, NFI-C, and NFI-X were also determined in different
human breast cancer cell lines (MCF-7, T-47D, ZR-75-1, and MDA-MB-231), in the transformed human epithelial cell
line MCF-10A, and in ZR-75-1 cells that were transfected with siRNAs directed against NFI-A, NFI-B, NFI-C, or NFI-X
for 48 h. The copy numbers of SULT1A1 in cell lines ZR-75-1, MCF-7, T-47D, MDA-MB-231, and MCF-10A were determined
using a pre-designed Custom Plus TaqMan® Copy Number kit from Life Technologies.
Results: In normal human liver samples, SULT1A1 mRNA level was positively associated with NFI-C. In different human
breast cancer and normal epithelial cell lines, SULT1A1 expression was positively correlated with NFI-B and
NFI-C. SULT1A1 expression was decreased 41% and 61% in ZR-75-1 cells treated with siRNAs against NFI-A and
NFI-C respectively. SULT1A1 gene expression was higher in cells containing more than one SULT1A1 copy numbers.
Conclusions: Our data suggests that SULT1A1 expression is regulated by NFI, as well as SULT1A1 copy number variation
in human breast cancer cell lines. These data provide a mechanistic basis for the differential expression of
SULT1A1 in different tissues and different physiological states of disease.
Keywords: SULT1A1, NFI, Human breast cancer cell lines, Gene expression regulation, siRNA transfection, Gene
copy numberBackground
Treatment of estrogen receptor- (ER-) positive breast
cancer with tamoxifen (TAM) has been the gold stand-
ard for the past 30 years [1]. TAM is also the only FDA-
approved breast cancer chemoprevention agent, as its
use is associated with decreased occurrence of contralat-
eral breast cancer in patients treated with adjuvant TAM
[2]. Both the therapeutic efficacy and adverse effects of* Correspondence: SAKadlubar@uams.edu
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distribution, and reproduction in any mediumTAM vary considerably among individuals [3]. In terms
of therapeutic efficacy, 4-hydroxy-TAM and endoxifen
are the major active metabolites of TAM. The detoxifica-
tion of 4-hydroxy-TAM is carried out by phase II enzymes
such as sulfotransferases, including SULT1A1 and uridine
diphosphate glucuronosyltransferase (UGTs) [4].
Sulfotransferases catalyze the transfer of a sulfonate
group from 3′-phosphoadenosine 5′ -phosphosulfate
(PAPS) to a range of xenobiotic and endogenous com-
pounds such as drugs, carcinogens, and steroid hormones
[5]. The human SULT1A subfamily consists of SULT1A1,d Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Yao-Borengasser et al. BMC Clinical Pathology 2014, 14:1 Page 2 of 7
http://www.biomedcentral.com/1472-6890/14/1SULT1A2, SULT1A3, and SULT1A4. SULT1A1 protein is
found in many different human tissues, with the highest
abundance found in the liver [6-11]. SULT1A1 activity var-
ies several-fold among individuals [12-14]. It has been
shown that gene expression/protein activity levels of
SULT1A1 affect the efficacy of TAM treatment [15-18].
SULT1A1 can also contribute to increased cancer risk (as
reviewed in [19]), including breast cancer risk [20-22].
Furthermore, SULT1A1 expression is related to disease
state, with little to no expression in normal breast epithelia
but plentiful protein expression in most breast tumors
[23,24]. Given the role that SULT1A1 plays in drug effi-
cacy and in individual susceptibility to disease, it is import-
ant to elucidate the factors regulating the differential
expression of SULT1A1.
Some studies have shown that single nucleotide poly-
morphisms (SNPs) in the human SULT1A1 promoter,
3′-untranslated region (UTR), and coding regions con-
tribute to SULT1A1 availability and activity [13,25-27].
However, SNPs account for only a small percentage of
the variation of SULT1A1 activity. Some studies demon-
strated that SULT1A1 gene copy number variants (CNV)
exist in human populations, and that CNV is associated
with SULT1A1 activity [13,28,29]. Nevertheless, doub-
ling SULT1A1 copy number does not appear to double
its activity, indicating that factors other than copy num-
ber are determinants of SULT1A1 activity. Thus, other
factors must play a role in regulating the expression of
SULT1A1. Traditionally, SULT1A1 has been considered
a non-inducible enzyme. Since its expression is variable
across tissues, it could be postulated that transcription
factor (TF) binding (and the tissue-specific availability of
TFs) may affect gene expression in SULT1A1. There
have been reports of TF regulation of SULT1A1. There
is one report that demonstrated that SULT1A1 promoter
activity is dependent on the presence of ubiquitous Ets
family transcription factors [30]. While these TFs appear
to be responsible for basal, constitutive expression, TFs
that affect differential SULT1A1 gene expression have
not been examined. In this study, TFs differentially
expressed between low SULT1A1-expressing transformed
epithelial mammary cells and high SULT1A1-expressing
breast cancer cells have been identified for the first time
using a TF Activation Profiling Plate Array assay.
Methods
Cell culture
The human breast cancer cell lines ZR-75-1, MCF-7,
T-47D, MDA-MB-231, and the human transformed mam-
mary epithelial cell line MCF-10A were purchased from
American Type Culture Collection (Rockville, MD) and
were sustained in a 37°C incubator containing 5% CO2.
ZR-75-1 cells were cultured in RPMI 1640 medium with
10% fetal bovine serum (FBS). MCF-7 cells were culturedin Improved MEM medium with 10% FBS and 0.01 mg/ml
insulin (Life Technologies, Carlsbad, CA). MDA-MB-231
cells were cultured in DMEM medium with 10% FBS.
MCF-10A cells were cultured in DMEM/F12 medium
supplemented with 5% chelex-treated horse serum (Life
Technologies), 20 mg/ml of epidermal growth factor (Life
Technologies), 10 μg/ml insulin (Sigma, St. Louis, MO),
0.5 g/ml hydrocortisone (Sigma), and 0.1 μg/ml cholera
toxin (Sigma).
Human subjects
Normal human liver samples (n = 84) were obtained from
the U.S. Cooperative Human Tissue Network under a
University of Arkansas for Medical Sciences Institutional
Research Committee-approved protocol. All specimens
were snap-frozen upon collection. Normal tissue status
was confirmed with histology by the Cooperative Human
Tissue Network. Samples included 33 women and 51
men, all of whom were Caucasian. The average age of the
study population was 59, ranging from 26 to 102.
Differential transcription factor activation assay
The differential TF activation profile in ZR-75-1 and MCF-
10A cells was determined using a TF Activation Profiling
Plate Array assay following the manufacturer’s instructions
(Signosis, Sunnyvale, CA). Briefly, 5 μg of nuclear extract
from ZR-75-1 or MCF-10A cells was hybridized with 48
different biotin-labeled probes that contain consensus se-
quences of TF DNA-binding sites. The TF-bound probes
were captured by complementary sequences of the probes
pre-coated on a 96-well plate. The captured probes were
detected with streptavidin-HRP. The levels of lumines-
cence of each corresponding well were quantitatively ana-
lyzed with Spectramax M5 (Sunnyvale, CA) and compared
between MCF-10A cells and ZR-75-1 cells.
Nuclear factor I (NF-I) siRNA treatment of ZR-75-1 cells
All siRNAs and transfection reagents were purchased from
Life Technologies. ZR-75-1 cells that were at the exponen-
tial growth stage were transfected with 50 pmol of pre-
designed siRNA against 4 NFI family members (NFI-A,
NFI-B, NFI-C, NFI-X) or 100pmol siGAPDH as a negative
control using Lipofectamine™ 2000 transfection reagent fol-
lowing the manufacturer’s instructions. After 48 h transfec-
tion, cells were collected for total RNA isolation. The
percentage of knockdown of target gene expression was
determined using quantitative RT-PCR (qRT-PCR). The se-
quences of siRNAs are listed in Table 1.
DNA and RNA isolation and quantitative real-time PCR
(qRT-PCR)
Total RNA and total DNA from cultured cells and from
snap-frozen human liver tissues were isolated with an
AllPrep® DNA/RNA/protein kit (QIAGEN, Valencia, CA)
Table 1 Primer sequences
Gene Sequences (forward) Sequences (reverse)
18S 5′ TTCGAACGTCTGCCCTATCAA 3′ 5′ ATGGTAGGCACGGCGACTA 3′
GAPDH 5′ ACAGTCAGCCGCATCTTCTT 3′ 5′ ACGACCAAATCCGTTGACTC 3′
NFI-A 5′ CCAGCGCCCGGCAGTTATGT 3′ 5′ ATTCATCCTGGGTGAGACAGAGCGG 3′
NFI-B 5′ AACCAGCCAGCCTAACGGCA 3′ 5′ TCGCACTGCACTGGGATGGG 3′
NFI-C 5′ GACATGGAAGGAGGCATCTC 3′ 5′ GGGCTGTTGAATGGTGACTT 3′
NFI-X 5′ CCACTGCCCAACGGGCACTTA 3′ 5′ CCGTCACATTCCAGACCCCGGA 3′
SULT1A1 5′ AGGAGTTCATGGACCACAGC3′ 5′ TGAAGGTGGTCTTCCAGTCC3′
siNFI-A 5′ GGUAUUCCGCUGGAAAGUAtt 3′
siNFI-B 5′ AGUGUCAUCUCAACUCGAAtt 3′
siNFI-C 5′ GGACAGGGCGUCUUCCUAAtt 3′
siNFI-X 5′ GAAUCCGGACAAUCAGAUAtt 3′
Figure 1 SULT1A1 mRNA levels in different cell lines. Total RNA
was isolated from cells that were cultured at exponential growth
stage. The mRNA levels of SULT1A1 in ZR-75-1, MCF-7, T-47D, MCF-10A,
and MDA-MB-231 were determined by real-time RT-PCR and were
normalized with 18S.
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and quality of the isolated RNA and DNA were determined
by an Agilent 2100 Bioanalyzer (Agilent Technology,
Palo Alto, CA). qRT-PCR using SYBR-green reagent was
performed and analyzed as described previously[31]. qRT-
PCR using TaqMan® reagents (Life Technologies) was car-
ried out as detailed previously [13]. The primer sequences
used with SYBR-green reagent are listed in Table 1.
Determination of SULT1A1 gene copy number
SULT1A1 gene was amplified by relative quantitative
PCR using a pre-designed Custom Plus TaqMan® Copy
Number kit following the company’s instructions (Life
Technologies). SULT1A1 copy number variations were cal-
culated using the Applied Biosystems CopyCaller™ software
(Life Technologies).
Statistical analysis
Paired t tests were used to compare baseline and treat-
ment measurements within a group. Pearson’s correlation
coefficients were used to describe the linear association
between variables. All data from samples were expressed
as mean ± sem.
Results
SULT1A1 Expression levels in different breast cancer
cell lines
Other laboratories have reported that expression of
SULT1A1 is very low in normal breast tissue as compared
to tumor tissue [23,24]. To test if this is also true in cul-
tured cells, the mRNA levels of SULT1A1 were determined
in the breast cancer cell lines ZR-75-1, MCF-7, T-47D,
MDA-MB-231 and the human transformed breast epithe-
lial cell line MCF-10A with relative qRT-PCR. Data were
analyzed as absolute quantification and expressed in rela-
tion to 18S RNA. Standard curves were generated using
pooled cDNA from the samples assayed. Figure 1 showsthat ZR-75-1 cells and T-47D cells had higher SULT1A1
mRNA levels compared to the other cell lines. Compared
to the phenotypically normal epithelial MCF-10A cells,
SULT1A1 expression was more than 3 times higher in ZR-
75-1 and T-47D cells. MCF-7 cells showed similar expres-
sion levels of SULT1A1 as MCF-10A cells. SULT1A1 was
not expressed in MDA-MB-231 cells.
Correlation of gene expressions between NFI family
genes and SULT1A1
One possible mechanism of differential SULT1A1 expres-
sion in different cell lines could be the availability of TFs.
To test this hypothesis, the TF Activation Profiling Plate
Array assay was performed in normal breast MCF-10A
cells and breast cancer ZR-75-1 cells. TF activation profile
differences in MCF-10A cells and ZR-75-1 cells were
quantitatively analyzed and compared as described in
Methods. Out of 48 TFs, 13 had at least 1.5 fold more
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10A cells (data not shown, see Additional file 1). After
matching the 13 TFs to the TF binding consensus se-
quences in SULT1A1 using Transcriptional Regulatory
Element Database software (Cold Spring Harbor, NY), NFI
and GATA transcription factor 1 (GATA-1) were chosen as
the transcription factors most likely to regulate SULT1A1
expression. SULT1A1 promoter contains a GATA-1 bind-
ing site (CCTGCCTATC) at position −367 bp and a NFI
binding site (TGTTGGCTGC) at position −298 bp. There
are four genes encoding NFI in humans, namely NFI-A,
NFI-B, NFI-C, and NFI-X. To determine the relationship
between NFI or GATA-1 and SULT1A1, mRNA levels of
each were measured using total RNA isolated from 84 nor-
mal human liver samples. As seen in Figure 2, TaqMan®
qRT-PCR results demonstrate that NFI-C (chosen as
a representative form of NFI) mRNA levels were signifi-
cantly correlated with SULT1A1 mRNA levels (r = 0.64,
p < 0.0001). GATA-1 mRNA level, on the other hand,
showed no association with SULT1A1 expression level
(r = 0.17, p = 0.11, see Additional file 2).
Next, gene expression correlations between SULT1A1
and all four individual NFI family genes in different cell
lines were explored. mRNA levels of NFI-A, NFI-B, NFI-C,
NFI-X, and SULT1A1 in MCF-10A, ZR-75-1, T-47D,
MCF-7, and MDA-MB-231 were determined by qRT-PCR
and normalized with 18S mRNA. SULT1A1 gene ex-
pression was highest in ZR-75-1 and T-47D cells, as were
NFI-B and NFI-C gene expression (Table 2). Pearson’s cor-
relation coefficients were used to describe the linear associ-
ation between SULT1A1 and NFI family gene expressions.
SULT1A1 mRNA levels were highly correlated across cell
lines with NFI-B (r = 0.95, p < 0.01) and NFI-C (r = 0.97,
p < 0.01). SULT1A1 mRNA levels showed a positive correl-
ation trend with NFI-A (r = 0.54) and NFI-X (r = 0.65) even
though the correlation coefficients did not reach statistical
significance (Table 2).Figure 2 Correlation between SULT1A1 mRNA and NFI-C mRNA
in Human liver. SULT1A1 mRNA level was highly correlated with
NFI-C mRNA level (r = 0.64, p < 0.0001). Real-time RT-PCR was performed
in liver samples taken from 84 healthy subjects as described in Methods.
Data was normalized with 18S.Regulation of SULT1A1 gene expression by NFI family genes
To determine if any of the four NFI genes has an effect
on SULT1A1 gene expression, ZR-75-1 cells, which have
the highest SULT1A1 gene expression in this study,
were transfected with siRNAs that were directed against
NFI-A, NFI-B, NIF-C, or NFI-X for 48 h as described
in Methods. The mRNA levels were determined by
relative RT-PCR, and the 2-ΔΔCT method was used [31].
As shown in Figure 3, mRNA levels of NFI-A (A), NFI-B
(B), NFI-C (C), and NFI-X (D) were reduced by 70% ±
0.02, 87% ± 0.08, 81% ± 0.08, and 86% ± 0.12, respectively.
SULT1A1 gene expression was significantly decreased by
41% ± 0.05 (p = 0.05) in siNFI-A (A) transfected cells and
64% ± 0.08 (p = 0.05) in siNFI-C (C) transfected cells. Al-
though not statistically significant, SULT1A1 mRNA levels
were also decreased in siNFI-B (B) (41% ± 0.16, p = 0.07)
and siNFI-X (D) transfected cells (53% ± 0.18, p = 0.15).
Further examination revealed that SULT1A1 gene expres-
sion was decreased more than four-fold in siNFI-B trans-
fected MCF-7 cells (data not shown, see Additional file 3).
To test whether different NFI TFs had an additive effect
on regulating SULT1A1 expression, ZR-75-1 cells were
also co-transfected with siNFI-A, siNFI-B, and siNFI-C for
48 h. As shown in Figure 3E, SULT1A1 mRNA level was
decreased about 40%, which is similar to that of each indi-
vidual NFI mRNA knockdown. Hence, the results indi-
cated that there was no additive transcriptional regulatory
effect on SULT1A1 expression by those three NFI TFs.
Relationship of SULT1A1 gene expression with its gene
copy number
Previous reports demonstrate that individual DNA con-
tains one to five copies of the SULT1A1 gene [28]. To
determine if CNV is also evident in different cell lines,
the CNV of SULT1A1 was determined in ZR-75-1,
MCF-7, T-47D, MDA-MB-231, and MCF-10A cell lines.
SULT1A1 copy numbers were calculated and normalized
to an endogenous reference gene RNase P, known to be
present in two copies in a diploid genome. Table 3 de-
tails the results of the calculated SULT1A1 copy num-
bers in the cell lines tested. Genomic DNA of MCF-7,
MDA-MB-231, and MCF-10A contains only one copy of
SULT1A1, while ZR-75-1 DNA has 3 copies and T-47D
DNA has 5 copies of SULT1A1.
To test if copy numbers correlate with SULT1A1 gene
expression level, the amount of mRNA of SULT1A1 and
corresponding SULT1A1 copy numbers were compared
in each cell line. The levels of mRNA were determined
by RT-PCR using a standard curve generated from
pooled cDNA samples from different cell lines. The data
was normalized with 18S and expressed as a ratio. As
shown in Table 3, cell lines with one copy of SULT1A1
(MCF-7 and MCF-10A) had lower gene expression, while
cell lines with more than one copy number (ZR-75-1 and
Table 2 Correlation of SULT1A1 mRNA level with NFI-A, NFI-B, NF-C, and NFI-X, mRNA levels in different cell lines
NFI-A/18S NFI-B/18S NFI-C/18S NFI-X/18S SULT1A1/18S
ZR-75-1 0.81 2.17 1.44 1.65 2.11
T-47D 4.08 2.55 1.43 0.93 1.74
MCF-7 0.04 0.21 0.70 0.36 0.54
MCF-10A 1.09 0.32 0.63 1.12 0.57
MDA-MB-231 0.47 0.08 0.57 0.83 0.00
Correlation coefficients of SULT1A1 mRNA with NFI family gene expressions (n = 5)
NFI-A NFI-B NFI-C NFI-X SULT1A1
Correlation coefficients 0.53 0.95 0.97 0.65 1.00
p value >0.1 <0.01 <0.01 >0.05
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cells expressed similar amount of SULT1A1 mRNA as
T-47D, even though ZR-75-1 DNA has two fewer copies
of SULT1A1 than T-47D cells. Although MDA-MB-231
DNA contains one copy of SULT1A1, there was no
SULT1A1 gene expression detected.
Discussion
SULT1A1 is expressed in different tissues, in different
physiological states of the same tissue, and in different
individuals. The factors that regulate SULT1A1 gene ex-
pression are poorly understood. Human studies show
that SULT1A1 can be regulated by alternative promoter
usage [32], SNPs in the coding or promoter region [26,27],A B
D
Figure 3 Effects of NFI siRNAs on SULT1A1 mRNA gene expression. Z
in Methods. Total RNA was extracted for gene expression analysis 48 h late
18S. *p < 0.05. A: SULT1A1 expression in siNFI-A treated cells. B: SULT1A1 e
treated cells. D: SULT1A1 expression in siNFI-X treated cells. E: SULT1A1 expCNVs [28], or variants in the 3′UTR of the gene [13].
However, these genetic variants account for only a portion
of the variation of SULT1A1 activity. Hempel et al. [30]
identified Ets synergized with Sp1 as one of the regulators
of SULT1A1 expression. It is postulated that ubiquitous
Ets is utilized to ensure constant expression of SULT1A1
in tissues such as liver, skin, and gut, since SULT1A1 is
important in xenobiotic metabolism. This current study
elucidated NFI gene family as an important TF in regulat-
ing SULT1A1 expression in different cell types.
The data presented here suggest that NFI may play a
major role in regulating SULT1A1 expression in differ-
ent physiological and disease states. The NFI family pro-
teins are associated with changes in different cell growthC
E
R-75-1 cells were treated with siRNA against NFI mRNAs as described
r (n = 3 for each mRNA expression level). Data was normalized with
xpression in siNFI-B treated cells. C: SULT1A1 expression in siNFI-C
ression in co-transfected siNFI-A, siNFI-B, and siNFI-C cells.
Table 3 Gene copy numbers and mRNA Levels
Cell line MCF-7 MDA-MB-231 MCF-10A ZR-75-1 T-47D
Copy number 1 1 1 3 5
SULT1A1 mRNA/18S 0.58 ± 0.03 0.00 0.75 ± 0.08 2.24 ± 0.21 2.17 ± 0.26
NFI-A mRNA/18S 0.06 ± 0.08 0.75 ± 0.00 0.93 ± 0.00 0.49 ± 0.00 4.48 ± 0.10
NFI-B mRNA/18S 0.22 ± 0.01 0.16 ± 0.01 0.19 ± 0.01 1.95 ± 0.17 3.51 ± 0.29
NFI-C mRNA/18S 0.62 ± 0.02 1.15 ± 0.05 0.80 ± 0.03 0.90 ± 0.02 1.64 ± 0.02
NFI-X mRNA/18S 0.49 ± 0.03 1.32 ± 0.7 1.14 ± 0.11 1.35 ± 0.16 1.08 ± 0.09
SULT1A1 copy numbers and gene expression levels of SULT1A1, NFI-A, NFI-B, NFI-C, and NFI-X were determined in different cell lines.
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as reviewed in [33-35]. TF profiling array data demon-
strated that NFI in high-SULT1A1-expressing ZR-75-1
breast cells was expressed more than in low-SULT1A1-
expressing non-cancer MCF-10A cells. This positive as-
sociation was also observed in human liver samples and
in different human cell lines. Further siRNA transfection
assays suggested that SULT1A1 expression is controlled,
at least partially, by NFI in breast cancer cells. While the
siRNA data demonstrate NFI-B has the least effect
on SULT1A1 expression, there is still an effect and
the p-value approached significance at p = 0.07, while the
NFI isoforms with significant effects were at p = 0.05. This
effect may not be a direct one, and NFI-B may not be the
only factor which has an effect on SULT1A1 expression.
Rather it may be part of another mechanism that has a
compound effect on SULT1A1 expression. This could
explain the lower significance of NFI-B. There was no
additive SULT1A1 expression inhibition observed when
ZR-75-1 cells were co-transfected with siNFI-A, siNFI-B,
and siNFI-C, suggesting that each gene has its own role in
regulating SULT1A1 expression.
NFI siRNA knockdown experiments inhibited about
40% of SULT1A1 expression in ZR-75-1 cells, suggesting
other regulatory mechanism(s) exist. Previous studies
have shown that the human population possesses one to
five copies of SULT1A1, and that its enzyme activity is
correlated with CNV [13,14,28]. The data presented here
demonstrate that there were SULT1A1 copy number dif-
ferences in human cell lines also, and that cells with
more copies had higher SULT1A1 expression than cells
with only one copy. However, higher copy number does
not always correlate with the degree of expression. T-47D
cells, which contained five copies, had similar SULT1A1
expression to that of ZR-75-1 cells, which contained three
copies. MCF-7 and MDA-MB-231cells each contained
one copy, yet MDA-MB-231 cells showed no SULT1A1
expression, while MCF-7 cells showed a modest amount
of SULT1A1 expression. The data suggests that SULT1A1
gene expression could also be regulated by mechanisms
other than NFI and copy numbers. SULT1A1 CNV in
different cell lines reflect the range of SULT1A1 CNVreported in human populations [13,14,28]. Thus, cell lines
could be used as a model for human SULT1A1 CNV-
related studies.
Conclusions
In summary, our data demonstrate that the NFI family of
transcription factors significantly contributes to the regula-
tion of SULT1A1 expression in human breast cancer cell
lines. Along with these TFs, SULT1A1 CNV determines
gene expression. Understanding the regulation of SULT1A1
expression will facilitate the prediction of drug response in
relation to breast cancer prevention and therapy.
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Additional files
Additional file 1: Differential transcription factor activities levels
between MCF-10A and ZR-75-1 cells. Transcription factor activation
profile was determined using a TF Activation Profiling Plate Array as
described in Methods. Data chosen from results showing that transcription
factor activation level in ZR-75-1 cells (black bar) was at least 1.5 fold higher
than that in MCF-10A cells (gray bar).
Additional file 2: Correlation between GATA-1 mRNA and NFI-C
mRNA in Human liver. Real-time RT-PCR was performed in liver samples
taken from healthy subjects as described in Methods. Data was normalized
with 18S. GATA-1 mRNA level was not correlated with SULT1A1 mRNA level
(r = 0.17, p = 0.11).
Additional file 3: Screening of SULT1A1 gene expression activators
from MCF-7 cells treated with siRNAs. SULT1A1 mRNA levels were
determined with The Expressed Transcription Factor Knockdown
Transcriptome PCR Array (Qiagen, Valencia, CA) following the manufacturer’s
instructions. Briefly, real-time PCR was performed with cDNAs derived from
MCF-7 cells treated with siRNAs targeting 270 transcription factors. SULT1A1
gene expression levels were expressed as Log2 fold changes based on Ct
calculation using 18S as house-keeping gene and non-target siRNA treated
sample well (VTC) as negative control. The arrow indicates SULT1A1
gene expression was decreased more than four-fold in siNFI-B transfected
MCF-7 cells.
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